LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 10 of 15: Cell count and normalized growth rate inhibition values within biological replicate 3. - Dataset (ID:20247)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Normalized Growth Rate Inhibition Value |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
MDA-MB-231 | Barasertib | 3.33 | uM | LJP5 | 2 | D08 | 72 | hr | 1235 | 1543 | 4578 | 0.3370 | 0.1246 |
MDA-MB-231 | Barasertib | 3.33 | uM | LJP5 | 3 | D08 | 72 | hr | 1235 | 1355 | 4929 | 0.2749 | 0.0472 |
MDA-MB-231 | Barasertib | 10 | uM | LJP5 | 1 | D07 | 72 | hr | 1235 | 1355 | 4474 | 0.3028 | 0.0508 |
MDA-MB-231 | Barasertib | 10 | uM | LJP5 | 2 | D07 | 72 | hr | 1235 | 1446 | 4578 | 0.3158 | 0.0866 |
MDA-MB-231 | Barasertib | 10 | uM | LJP5 | 3 | D07 | 72 | hr | 1235 | 1392 | 4929 | 0.2824 | 0.0614 |
MDA-MB-231 | Vemurafenib | 0.04 | uM | LJP5 | 1 | C18 | 72 | hr | 1235 | 4859 | 4474 | 1.0859 | 1.0908 |
MDA-MB-231 | Vemurafenib | 0.04 | uM | LJP5 | 2 | C18 | 72 | hr | 1235 | 4836 | 4578 | 1.0562 | 1.0588 |
MDA-MB-231 | Vemurafenib | 0.04 | uM | LJP5 | 3 | C18 | 72 | hr | 1235 | 4541 | 4929 | 0.9212 | 0.9195 |
MDA-MB-231 | Vemurafenib | 0.12 | uM | LJP5 | 1 | C17 | 72 | hr | 1235 | 4583 | 4474 | 1.0242 | 1.0259 |
MDA-MB-231 | Vemurafenib | 0.12 | uM | LJP5 | 2 | C17 | 72 | hr | 1235 | 4685 | 4578 | 1.0232 | 1.0245 |
MDA-MB-231 | Vemurafenib | 0.12 | uM | LJP5 | 3 | C17 | 72 | hr | 1235 | 4678 | 4929 | 0.9490 | 0.9483 |
MDA-MB-231 | Vemurafenib | 0.37 | uM | LJP5 | 1 | C16 | 72 | hr | 1235 | 4637 | 4474 | 1.0363 | 1.0388 |
MDA-MB-231 | Vemurafenib | 0.37 | uM | LJP5 | 2 | C16 | 72 | hr | 1235 | 4692 | 4578 | 1.0248 | 1.0261 |
MDA-MB-231 | Vemurafenib | 0.37 | uM | LJP5 | 3 | C16 | 72 | hr | 1235 | 4513 | 4929 | 0.9156 | 0.9135 |
MDA-MB-231 | Vemurafenib | 1.11 | uM | LJP5 | 1 | C15 | 72 | hr | 1235 | 4166 | 4474 | 0.9310 | 0.9244 |
MDA-MB-231 | Vemurafenib | 1.11 | uM | LJP5 | 2 | C15 | 72 | hr | 1235 | 4627 | 4578 | 1.0106 | 1.0112 |
MDA-MB-231 | Vemurafenib | 1.11 | uM | LJP5 | 3 | C15 | 72 | hr | 1235 | 4320 | 4929 | 0.8764 | 0.8721 |
MDA-MB-231 | Vemurafenib | 3.33 | uM | LJP5 | 1 | C14 | 72 | hr | 1235 | 4115 | 4474 | 0.9196 | 0.9117 |
MDA-MB-231 | Vemurafenib | 3.33 | uM | LJP5 | 2 | C14 | 72 | hr | 1235 | 4115 | 4578 | 0.8988 | 0.8901 |
MDA-MB-231 | Vemurafenib | 3.33 | uM | LJP5 | 3 | C14 | 72 | hr | 1235 | 4444 | 4929 | 0.9016 | 0.8988 |
MDA-MB-231 | Vemurafenib | 10 | uM | LJP5 | 1 | C13 | 72 | hr | 1235 | 2106 | 4474 | 0.4706 | 0.3326 |
MDA-MB-231 | Vemurafenib | 10 | uM | LJP5 | 2 | C13 | 72 | hr | 1235 | 2395 | 4578 | 0.5231 | 0.4193 |
MDA-MB-231 | Vemurafenib | 10 | uM | LJP5 | 3 | C13 | 72 | hr | 1235 | 2339 | 4929 | 0.4745 | 0.3766 |
MDA-MB-231 | Enzastaurin | 0.04 | uM | LJP5 | 1 | D18 | 72 | hr | 1235 | 4495 | 4474 | 1.0045 | 1.0049 |
MDA-MB-231 | Enzastaurin | 0.04 | uM | LJP5 | 2 | D18 | 72 | hr | 1235 | 4868 | 4578 | 1.0632 | 1.0660 |